May 28 (UPI) -- AstraZeneca reached a deal with British gene and cell therapy company Oxford Biomedica on Thursday to produce its potential vaccine for COVID-19.
Under the agreement, Oxford Biomedica announced it will give AstraZeneca access to its manufacturing center and produce multiple batches of the vaccine candidate, known as AZD1222, this year.